GlassScriptPhysician profile
Irma Vega Lopez
NPI 1194778274
$2,264.57
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $30.89 · 2021: $215 · 2022: $279 · 2023: $381 · 2024: $462 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $494.60 | 2019-2025 | Repatha, Evenity, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.52 | 2019-2024 | Xifaxan |
| Pfizer INC. | $233.28 | 2019-2024 | |
| Silk Road Medical, INC. | $151.52 | 2019 | |
| Eisai INC. | $124.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $111.52 | 2019-2025 | |
| Abbvie INC. | $109.53 | 2021-2025 | |
| Exact Sciences Corporation | $90.74 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $89.75 | 2019-2024 | Wegovy |
| Amarin Pharma, INC. | $85.72 | 2019-2021 | |
| Lilly USA, LLC | $77.47 | 2021-2025 | Kisunla, Jardiance |
| Regeneron Healthcare Solutions, INC. | $56.33 | 2019 | |
| Abiomed | $50.56 | 2021 | |
| Insmed, INC. | $47.62 | 2025 | Brinsupri, Arikayce |
| Astrazeneca Pharmaceuticals LP | $39.62 | 2019-2023 | Breztri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $35.73 | 2025 | Rexulti |
| Allergan, INC. | $25.90 | 2019-2020 | |
| Hologic Sales and Service, LLC | $24.83 | 2023 | Aptima, Thinprep 2000 Processor |
| Radius Health, INC. | $24.29 | 2024 | Tymlos |
| Glaxosmithkline, LLC. | $23.99 | 2024 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $22.99 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.14 | 2019 | |
| Mylan Specialty L.P. | $19.94 | 2019 | |
| Merck Sharp & Dohme LLC | $16.07 | 2025 | Capvaxive |
| Idorsia Pharmaceuticals US INC | $15.83 | 2024 | Quviviq |
| Lundbeck LLC | $15.09 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irma Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.